Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Denitrification in a hypersaline lake-aquifer system (Pétrola Basin, Central Spain): the role of recent organic matter and Cretaceous organic rich sediments.
Gómez-Alday JJ, Carrey R, Valiente N, Otero N, Soler A, Ayora C, Sanz D, Muñoz-Martín A, Castaño S, Recio C, Carnicero A, Cortijo A. Gómez-Alday JJ, et al. Sci Total Environ. 2014 Nov 1;497-498:594-606. doi: 10.1016/j.scitotenv.2014.07.129. Epub 2014 Aug 27. Sci Total Environ. 2014. PMID: 25169874
Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients' healthcare in Spain.
Muñoz Martín A, Trujillo-Santos AJ, Martí E, Jara-Palomares L, Macías Montero R, Gallardo E, López-Núñez JJ, Brozos-Vázquez E, Robles-Marinas V, Pérez-Segura P, Ruíz-Artacho P. Muñoz Martín A, et al. Clin Transl Oncol. 2024 Jun;26(6):1319-1328. doi: 10.1007/s12094-023-03379-z. Epub 2024 Feb 13. Clin Transl Oncol. 2024. PMID: 38349577
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group.
Sánchez Cánovas M, Fernández Garay D, Gómez Martínez F, Brozos Vázquez E, Lobo de Mena M, García Adrián S, Pacheco-Barcía V, Cacho Lavin D, Martínez de Castro E, Martín Fernández de Soignie AM, Martínez E, Rúperez Blanco AB, García Escobar I, Salvador Coloma C, Blaya Boluda N, Guirao García ME, Gambín Arroniz M, Muñoz Martín AJ. Sánchez Cánovas M, et al. Among authors: munoz martin aj. Clin Transl Oncol. 2024 Jan;26(1):171-177. doi: 10.1007/s12094-023-03233-2. Epub 2023 Jun 10. Clin Transl Oncol. 2024. PMID: 37301805 Free PMC article.
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study.
Sánchez-Cánovas M, Jimenez-Fonseca P, Fernández Garay D, Cejuela Solís M, Casado Elía D, Coma Salvans E, de la Haba Vacas I, Gómez Sánchez D, Fernández Montés A, Morales Giménez R, Biosca Gómez de Tejada M, Arrazubi Arrula V, Sequero López S, Otero Candelera R, Sánchez Cendra C, Justo de la Peña M, Moreno Muñoz D, Orillo Sarmiento M, Martínez de Castro E, García Escobar I, Bernal Vidal A, Ortega Moran L, Muñoz Martín AJ, Sánchez Bayona R, Martínez Ortiz MJ, Ayala de la Peña F, Vicente V, Carmona-Bayonas A. Sánchez-Cánovas M, et al. Among authors: munoz martin aj. PLoS One. 2023 May 9;18(5):e0266305. doi: 10.1371/journal.pone.0266305. eCollection 2023. PLoS One. 2023. PMID: 37159465 Free PMC article.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
53 results